Elanco Animal Health Incorporated Common Stock
ELANElanco Animal Health Incorporated is a global company focused on developing, manufacturing, and marketing products for animal health. It specializes in veterinary pharmaceuticals, vaccines, and nutritional products aimed at enhancing the health and well-being of pets and livestock. Founded in 1954 and headquartered in Greenfield, Indiana, Elanco serves a broad customer base across multiple markets, emphasizing innovation in animal healthcare.
Company News
The global Veterinary API Manufacturing Market is projected to grow from USD 7.21 billion in 2025 to USD 18.48 billion by 2035, driven by rising zoonotic disease prevention efforts, increasing pet ownership, and expanding animal healthcare investments. The market is segmented by service type, synthesis type, therapeutic category, and animal type,...
Elanco Animal Health (NYSE: ELAN) shares rose 9.33% following better-than-expected Q1 earnings of 40 cents per share (vs. 35 cents consensus) and $1.37 billion in sales (vs. $1.29 billion consensus). The company raised full-year guidance and reported strong growth across both Pet Health and Farm Animal segments, driven by new product launches and...
PRISM MarketView launched the PRISM PetCare Index to track publicly traded companies driving growth in the global pet care sector, projected to exceed $350 billion. The index includes companies advancing veterinary services, pet pharmaceuticals, insurance, diagnostics, and premium nutrition. Key companies highlighted include Elanco Animal Health,...
Zoetis is set to report Q4 2025 earnings on Feb. 12 after disappointing guidance last quarter caused an 11% stock decline. While the company has beaten earnings in four consecutive quarters and lowered expectations could set up positive surprises, investors remain concerned about persistent macro headwinds affecting its livestock business and ost...
The global canine glucosamine supplement market is experiencing rapid growth, expanding from USD 236.44 million in 2025 to USD 257.55 million in 2026, with a projected CAGR of 7.27% through 2032, reaching USD 386.54 million. Market growth is driven by increased pet ownership, higher consumer spending on veterinary wellness, product innovation in ...
